A
Amy Wesa
Researcher at University of Pittsburgh
Publications - 28
Citations - 1789
Amy Wesa is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Immune system & Cytotoxic T cell. The author has an hindex of 17, co-authored 25 publications receiving 1689 citations.
Papers
More filters
Journal ArticleDOI
Interleukin-12: biological properties and clinical application.
Michele Del Vecchio,Emilio Bajetta,Stefania Canova,Michael T. Lotze,Amy Wesa,Giorgio Parmiani,Andrea Anichini +6 more
TL;DR: More effective application of this cytokine, and of newly identified IL-12 family members (IL-23 and IL-27), should be evaluated as therapeutic agents with considerable potential in cancer patients.
Journal ArticleDOI
α-Type-1 Polarized Dendritic Cells A Novel Immunization Tool with Optimized CTL-inducing Activity
Robbie B. Mailliard,Anna Wankowicz-Kalinska,Quan Cai,Amy Wesa,Catharien M. U. Hilkens,Martien L. Kapsenberg,John M. Kirkwood,Walter J. Storkus,Pawel Kalinski +8 more
TL;DR: Serum-free generation of alphaDC1 allows, for the first time, the clinical application of DCs that combine the key three features important for their efficacy as anticancer vaccines.
Journal ArticleDOI
A novel probe for the non-invasive detection of tumor-associated inflammation
Anthony Balducci,Yi Wen,Yang Zhang,Brooke M. Helfer,T. Kevin Hitchens,Wilson S. Meng,Amy Wesa,Jelena M. Janjic +7 more
TL;DR: A novel dual-mode contrast agent formulated through the addition of an optical near infrared (NIR) probe to a perfluorocarbon (PFC)-based 19F magnetic resonance imaging (MRI) agent could serve as a valuable tool for evaluating novel anticancer agents.
Journal ArticleDOI
Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro.
TL;DR: The results suggest that preexisting CD4+ T cell immunity to cancer is not relegated to Type-1 insufficiency and may be corrected via the application of DC1-based vaccination protocols.
Journal ArticleDOI
Effect of renal cell carcinomas on the development of type 1 T-cell responses
Patricia Rayman,Amy Wesa,Amy Richmond,Tanya Das,Kaushik Biswas,Gira Raval,Walter J. Storkus,Charles S. Tannenbaum,Andrew C. Novick,Ronald M. Bukowski,James H. Finke +10 more
TL;DR: It is proposed that renal cell carcinoma-derived tumor products such as gangliosides can induce a type 2 bias in antitumor immunity by initiating apoptosis in the IFN-γ-producing type 1 effector cells.